MX384828B - Formas solidas cristalinas de n-{4-[(6,7-dimetoxiquinolin-4-il)oxi]fenil}-n'-(4-fluorofenil)ciclopropan-1,1-dicarboxamida, procesos para elaboracion y metodos de uso. - Google Patents

Formas solidas cristalinas de n-{4-[(6,7-dimetoxiquinolin-4-il)oxi]fenil}-n'-(4-fluorofenil)ciclopropan-1,1-dicarboxamida, procesos para elaboracion y metodos de uso.

Info

Publication number
MX384828B
MX384828B MX2016010266A MX2016010266A MX384828B MX 384828 B MX384828 B MX 384828B MX 2016010266 A MX2016010266 A MX 2016010266A MX 2016010266 A MX2016010266 A MX 2016010266A MX 384828 B MX384828 B MX 384828B
Authority
MX
Mexico
Prior art keywords
crystalline solid
solid forms
cancer
dimethoxyquinolin
dicarboxamide
Prior art date
Application number
MX2016010266A
Other languages
English (en)
Spanish (es)
Other versions
MX2016010266A (es
Inventor
Dana T Aftab
Jana Galbraith
Khalid Shah
Nathan Guz
Noel Hamill
Simon Yau
Stephen Lau
Tracy Walker
Original Assignee
Exelixis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exelixis Inc filed Critical Exelixis Inc
Publication of MX2016010266A publication Critical patent/MX2016010266A/es
Publication of MX384828B publication Critical patent/MX384828B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/233—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
MX2016010266A 2014-02-14 2015-02-16 Formas solidas cristalinas de n-{4-[(6,7-dimetoxiquinolin-4-il)oxi]fenil}-n'-(4-fluorofenil)ciclopropan-1,1-dicarboxamida, procesos para elaboracion y metodos de uso. MX384828B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461939985P 2014-02-14 2014-02-14
PCT/US2015/016052 WO2015123639A1 (en) 2014-02-14 2015-02-16 Crystalline solid forms of n-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-n'-(4-fluorophenyl) cyclopropane-1, 1-dicarboxamide, processes for making, and methods of use

Publications (2)

Publication Number Publication Date
MX2016010266A MX2016010266A (es) 2017-02-08
MX384828B true MX384828B (es) 2025-03-14

Family

ID=52684662

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2016010266A MX384828B (es) 2014-02-14 2015-02-16 Formas solidas cristalinas de n-{4-[(6,7-dimetoxiquinolin-4-il)oxi]fenil}-n'-(4-fluorofenil)ciclopropan-1,1-dicarboxamida, procesos para elaboracion y metodos de uso.
MX2021001583A MX2021001583A (es) 2014-02-14 2015-02-16 Formas sólidas cristalinas de n-{4-[(6,7-dimetoxiquinolin-4-il)oxi ] fenil}-n'-(4-fluorofenil)ciclopropan-1,1-dicarboxamida, procesos para elaboración y métodos de uso.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021001583A MX2021001583A (es) 2014-02-14 2015-02-16 Formas sólidas cristalinas de n-{4-[(6,7-dimetoxiquinolin-4-il)oxi ] fenil}-n'-(4-fluorofenil)ciclopropan-1,1-dicarboxamida, procesos para elaboración y métodos de uso.

Country Status (14)

Country Link
US (5) US10501418B2 (OSRAM)
EP (2) EP3738952A1 (OSRAM)
JP (2) JP6756617B2 (OSRAM)
KR (1) KR102354963B1 (OSRAM)
CN (1) CN106068255A (OSRAM)
AU (3) AU2015218236B2 (OSRAM)
BR (1) BR112016018450A2 (OSRAM)
CA (2) CA2939546C (OSRAM)
EA (1) EA032757B1 (OSRAM)
IL (1) IL247035B2 (OSRAM)
MX (2) MX384828B (OSRAM)
UA (1) UA123534C2 (OSRAM)
WO (1) WO2015123639A1 (OSRAM)
ZA (1) ZA201605424B (OSRAM)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105693720B (zh) 2010-05-20 2019-01-18 阵列生物制药公司 作为trk激酶抑制剂的大环化合物
KR102276348B1 (ko) 2013-03-15 2021-07-12 엑셀리시스, 인코포레이티드 Ｎ­（４­〔［６,７­비스（메틸옥시）퀴놀린­４­일］옥시〕페닐）­ｎ′­（４­플루오로페닐）시클로프로판­１,１­디카복사미드의 대사물
US11564915B2 (en) 2013-04-04 2023-01-31 Exelixis, Inc. Cabozantinib dosage form and use in the treatment of cancer
BR112016018450A2 (pt) 2014-02-14 2018-09-18 Exelixis Inc formas sólidas cristalinas de n-{4-[(6,7-dimetoxiquinolin-4-il)oxi]fenil}-n'-(4-fluorofenil)ciclopropano-1,1-dicarboxamida, processos de preparo e métodos de uso
EA201691850A1 (ru) 2014-03-17 2016-12-30 Экселиксис, Инк. Дозирование составов, содержащих кабозантиниб
MA40386A (fr) 2014-07-31 2016-02-04 Exelixis Inc Procédé de préparation de cabozantinib marqué au fluor-18 et d'analogues de celui-ci
EA034992B1 (ru) 2014-08-05 2020-04-15 Экселиксис, Инк. Комбинации лекарственных средств для лечения множественной миеломы
EP3322706B1 (en) 2015-07-16 2020-11-11 Array Biopharma, Inc. Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
RU2748549C2 (ru) 2016-04-15 2021-05-26 Экселиксис, Инк. Способ лечения почечно-клеточного рака с использованием n-(4-(6,7-диметоксихинолин-4-илокси)фенил)-n'-(4-фторфенил)циклопропан-1,1-дикарбоксамида, (2s)-гидроксибутандиоата
JOP20190077A1 (ar) 2016-10-10 2019-04-09 Array Biopharma Inc مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret
TWI704148B (zh) 2016-10-10 2020-09-11 美商亞雷生物製藥股份有限公司 作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
WO2018104954A1 (en) * 2016-12-07 2018-06-14 Msn Laboratories Private Limited, R&D Center Process for the preparation of n-(4-(6,7-dimethoxyquinolin-4-yloxy) phenyl)-n'-(4-fluorophenyl)cyclopropane-1, 1-dicarboxamide, (2s)-hydroxybutanedioate and its polymorphs thereof
WO2018136663A1 (en) 2017-01-18 2018-07-26 Array Biopharma, Inc. Ret inhibitors
CN110267960B (zh) 2017-01-18 2022-04-26 阿雷生物药品公司 作为RET激酶抑制剂的取代的吡唑并[1,5-a]吡嗪化合物
CA3049452A1 (en) * 2017-01-20 2018-07-26 Gisela Schwab Combinations of cabozantinib and atezolizumab to treat cancer
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
ES2909390T3 (es) * 2017-05-26 2022-05-06 Exelixis Inc Formas sólidas cristalinas de sales de N-{4-[(6,7-dimetoxiquinolin-4-il)oxi]fenil}-N'-(4-fluorofenil)ciclopropano-1,1-dicarboxamida, procedimientos de fabricación y procedimientos de uso
UA126402C2 (uk) 2017-06-09 2022-09-28 Екселіксіс, Інк. Рідка лікарська форма для лікування раку
TWI791053B (zh) 2017-10-10 2023-02-01 美商亞雷生物製藥股份有限公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物
TWI812649B (zh) 2017-10-10 2023-08-21 美商絡速藥業公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物
CN107951850A (zh) * 2017-12-20 2018-04-24 深圳万乐药业有限公司 一种苹果酸卡博替尼片的制备方法
WO2019143994A1 (en) 2018-01-18 2019-07-25 Array Biopharma Inc. Substituted pyrazolyl[4,3-c]pyridinecompounds as ret kinase inhibitors
TW201938169A (zh) 2018-01-18 2019-10-01 美商亞雷生物製藥股份有限公司 作為RET激酶抑制劑之經取代吡唑并[3,4-d]嘧啶化合物
CN111971286B (zh) 2018-01-18 2023-04-14 阿雷生物药品公司 作为RET激酶抑制剂的取代的吡咯并[2,3-d]嘧啶化合物
CN117624045A (zh) 2018-01-26 2024-03-01 埃克塞里艾克西斯公司 用于治疗激酶依赖性病症的化合物
CN113292537B (zh) 2018-06-15 2024-04-05 汉达癌症医药责任有限公司 激酶抑制剂的盐类及其组合物
ES2922314T3 (es) 2018-09-10 2022-09-13 Array Biopharma Inc Compuestos heterocíclicos condensados como inhibidores de cinasa RET
RS67216B1 (sr) 2018-12-13 2025-10-31 Exelixis Inc Kristalni oblici i oblici soli inhibitora kinaze
CA3202761A1 (en) 2020-11-25 2022-06-02 Nanocopoeia, Llc Amorphous cabozantinib particles and uses thereof
WO2022177983A1 (en) * 2021-02-19 2022-08-25 Slayback Pharma Llc Pharmaceutical compositions of cabozantinib
AU2024215796A1 (en) 2023-01-31 2025-05-15 Handa Oncology, Llc Improved cabozantinib compositions and methods of use
US11814356B1 (en) 2023-03-29 2023-11-14 Apotex Inc. Salt of cabozantinib

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2744997A1 (en) 2003-09-26 2005-04-07 Exelixis, Inc. C-met modulators and method of use
AU2005270068B2 (en) 2004-07-02 2012-04-19 Exelixis, Inc. C-Met modulators and method of use
AU2006231646A1 (en) 2005-04-06 2006-10-12 Exelixis, Inc. C-Met modulators and methods of use
AU2007334402B2 (en) 2006-12-14 2014-02-13 Exelixis, Inc. Methods of using MEK inhibitors
UY31800A (es) 2008-05-05 2009-11-10 Smithkline Beckman Corp Metodo de tratamiento de cancer usando un inhibidor de cmet y axl y un inhibidor de erbb
UY32142A (es) 2008-09-26 2010-05-31 Smithkline Beckman Corp Preparación de una quinoliniloxidifenilciclopropanodicarboxamida
JP5486606B2 (ja) 2008-11-13 2014-05-07 エクセリクシス， インク． キノリン誘導体の調製方法
JP2012511017A (ja) 2008-12-04 2012-05-17 エグゼリクシス， インコーポレイテッド キノリン誘導体の調製方法
KR101733773B1 (ko) * 2009-01-16 2017-05-10 엑셀리시스, 인코포레이티드 Ｎ-（４-｛〔６，７-비스（메틸옥시）퀴놀린-4-일〕옥시｝페닐）-ｎ＇-（４-플루오로페닐）사이클로프로판-1,1-디카르복사미드의 말산염 및 그 결정형
AU2010274012A1 (en) 2009-07-17 2012-02-09 Exelixis, Inc. Crystalline forms of N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy] -quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1, 1-dicarboxamide
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
SG184040A1 (en) 2010-03-12 2012-10-30 Exelixis Inc Hydrated crystalline forms of n-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]-quinolin-4-yl}oxy)phenyl]-n'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
US20120070368A1 (en) 2010-04-16 2012-03-22 Exelixis, Inc. Methods of Using C-Met Modulators
SG10201609324UA (en) 2010-07-16 2017-01-27 Exelixis Inc C-met modulator pharmaceutical compositions
EP2593091A1 (en) 2010-07-16 2013-05-22 Exelixis, Inc. C-met modulator pharmaceutical compositions
US20140057908A1 (en) 2010-09-27 2014-02-27 Exelixis, Inc. Method of Treating Cancer
CA2812750C (en) 2010-09-27 2020-10-06 Exelixis, Inc. Dual inhibitors of met and vegf for the treatment of castration-resistant prostate cancer and osteoblastic bone metastases
AU2011307306A1 (en) 2010-09-27 2013-05-02 Exelixis, Inc. Dual inhibitors of MET and VEGF for the treatment of castration resistant prostate cancer and osteoblastic bone metastases
JP2013543011A (ja) 2010-11-22 2013-11-28 グラクソスミスクライン、インテレクチュアル、プロパティー、ナンバー２、リミテッド 癌の治療法
GEP20247677B (en) 2011-02-10 2024-10-10 Exelixis Inc Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds
US20120252840A1 (en) 2011-04-04 2012-10-04 Exelixis, Inc. Method of Treating Cancer
JP2014513129A (ja) 2011-05-02 2014-05-29 エクセリクシス， インク． 癌および骨癌疼痛の治療方法
TW201306842A (zh) 2011-06-15 2013-02-16 Exelixis Inc 使用ｐｉ３ｋ／ｍｔｏｒ吡啶並嘧啶酮抑制劑及苯達莫司汀及／或利妥昔單抗治療惡性血液疾病之組合療法
AU2012312364B2 (en) 2011-09-22 2017-11-09 Exelixis, Inc. Method for treating osteoporosis
CN104395284A (zh) 2011-10-20 2015-03-04 埃克塞里艾克西斯公司 制备喹啉衍生物的方法
WO2013066296A1 (en) 2011-10-31 2013-05-10 Hewlett-Packard Development Company, L.P. Method of fabricating a color filter array using a multilevel structure
KR20140094597A (ko) 2011-11-08 2014-07-30 엑셀리시스, 인코포레이티드 암 치료를 정량하는 방법
BR112014011009A2 (pt) 2011-11-08 2017-06-06 Exelixis Inc inibidor duplo de met e vegf para tratar câncer
JP2015515988A (ja) 2012-05-02 2015-06-04 エクセリクシス， インク． 溶骨性骨転移を治療するためのｍｅｔ−ｖｅｇｆ二重調節剤
CN104703600A (zh) 2012-09-07 2015-06-10 埃克塞里艾克西斯公司 用于治疗肺腺癌的met、vegfr和ret的抑制剂
CN103664776B (zh) * 2012-09-26 2016-05-04 正大天晴药业集团股份有限公司 一种酪氨酸激酶抑制剂及其中间体的制备方法
US20140221372A1 (en) 2013-02-06 2014-08-07 GlaxoSmithKline Intellectual Property (NO 2.) Limited Method of administration and treatment
KR102276348B1 (ko) 2013-03-15 2021-07-12 엑셀리시스, 인코포레이티드 Ｎ­（４­〔［６,７­비스（메틸옥시）퀴놀린­４­일］옥시〕페닐）­ｎ′­（４­플루오로페닐）시클로프로판­１,１­디카복사미드의 대사물
BR112015025408A8 (pt) 2013-04-04 2018-07-10 Exelixis Inc combinações de drogas para tratar câncer
US11564915B2 (en) 2013-04-04 2023-01-31 Exelixis, Inc. Cabozantinib dosage form and use in the treatment of cancer
CN104370811B (zh) * 2013-08-15 2019-02-12 广东东阳光药业有限公司 一种喹啉化合物的新晶型及其制备方法
CN103664778B (zh) 2013-11-27 2017-04-05 苏州摩尔医药有限公司 一种抗肿瘤治疗药物卡博替尼的合成方法
BR112016018450A2 (pt) 2014-02-14 2018-09-18 Exelixis Inc formas sólidas cristalinas de n-{4-[(6,7-dimetoxiquinolin-4-il)oxi]fenil}-n'-(4-fluorofenil)ciclopropano-1,1-dicarboxamida, processos de preparo e métodos de uso
EA201691850A1 (ru) 2014-03-17 2016-12-30 Экселиксис, Инк. Дозирование составов, содержащих кабозантиниб
MA40386A (fr) 2014-07-31 2016-02-04 Exelixis Inc Procédé de préparation de cabozantinib marqué au fluor-18 et d'analogues de celui-ci
EA034992B1 (ru) 2014-08-05 2020-04-15 Экселиксис, Инк. Комбинации лекарственных средств для лечения множественной миеломы
TW201625243A (zh) 2014-10-14 2016-07-16 艾克塞里克斯公司 用於治療黑素瘤之藥物組合
ES2909390T3 (es) * 2017-05-26 2022-05-06 Exelixis Inc Formas sólidas cristalinas de sales de N-{4-[(6,7-dimetoxiquinolin-4-il)oxi]fenil}-N'-(4-fluorofenil)ciclopropano-1,1-dicarboxamida, procedimientos de fabricación y procedimientos de uso

Also Published As

Publication number Publication date
CA2939546C (en) 2023-01-17
JP2019163337A (ja) 2019-09-26
NZ723714A (en) 2021-03-26
US20210206722A1 (en) 2021-07-08
KR20160121544A (ko) 2016-10-19
US10501418B2 (en) 2019-12-10
EP3105204A1 (en) 2016-12-21
MX2021001583A (es) 2023-02-08
US12486233B2 (en) 2025-12-02
US20210198205A1 (en) 2021-07-01
US20170044106A1 (en) 2017-02-16
AU2019226302A1 (en) 2019-09-26
WO2015123639A1 (en) 2015-08-20
BR112016018450A2 (pt) 2018-09-18
UA123534C2 (uk) 2021-04-21
US11760726B2 (en) 2023-09-19
AU2015218236B2 (en) 2019-06-13
EA032757B1 (ru) 2019-07-31
IL247035B (en) 2022-11-01
US11724986B2 (en) 2023-08-15
JP2017505796A (ja) 2017-02-23
AU2019226302B2 (en) 2021-04-01
AU2015218236A1 (en) 2016-09-15
MX2016010266A (es) 2017-02-08
ZA201605424B (en) 2022-12-21
EP3738952A1 (en) 2020-11-18
CA2939546A1 (en) 2015-08-20
CA3181899A1 (en) 2015-08-20
US10851061B2 (en) 2020-12-01
US20230382867A1 (en) 2023-11-30
IL247035B2 (en) 2023-03-01
KR102354963B1 (ko) 2022-01-21
AU2021204278A1 (en) 2021-07-22
AU2021204278B2 (en) 2023-10-26
IL247035A0 (en) 2016-09-29
CN106068255A (zh) 2016-11-02
EA201691629A1 (ru) 2016-11-30
JP6756617B2 (ja) 2020-09-16
US20200190033A1 (en) 2020-06-18

Similar Documents

Publication Publication Date Title
MX384828B (es) Formas solidas cristalinas de n-{4-[(6,7-dimetoxiquinolin-4-il)oxi]fenil}-n'-(4-fluorofenil)ciclopropan-1,1-dicarboxamida, procesos para elaboracion y metodos de uso.
PH12019550050A1 (en) Isoxazole analogs as fxr agonists and methods of use thereof
MD20170016A2 (ro) Compuşi aminopirimidinici ca inhibitori JAK
MX2021001091A (es) Compuestos para usarse en el tratamiento o mejoramiento de la enfermedad de huntington.
EA201891191A1 (ru) 2-замещенные соединения хиназолина, содержащие замещенную гетероциклическую группу, и способы их применения
EA201690752A1 (ru) Ингибиторы g12c kras
MX2017008518A (es) Compuestos de isoquinolina para el tratamiento de virus de inmunodeficiencia humana (vih).
PH12015502615B1 (en) Chemical compounds
AU2018272088A8 (en) Crystalline solid forms of salts of N-{4-[(6,7-dimethoxyquinolin-4-yl) oxy]phenyl}-N'-(4-fluorphenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of use
PH12017500367A1 (en) Compounds that inhibit mcl-1 protein
MX2016002544A (es) Compuestos utiles como inmunomoduladores.
EA201592068A1 (ru) Ингибиторы энхансера zeste гомолога 2
PH12018500987A1 (en) Dihydroimidazopyrazinone derivatives useful in the treatment of cancer
EA201591890A1 (ru) Производные n-фенилкарбоксамида и их применение в качестве лекарственных препаратов для лечения гепатита b
MX363347B (es) Sal de omecamtiv mecarbilo y proceso para preparar la sal.
TN2015000574A1 (en) Compounds and compositions as inhibitors of mek
MX2015010829A (es) Compuestos terapeuticos y sus usos.
PH12018500446A1 (en) Pyridinone dicarboxamide for use as bromodomain inhibitors
TW201613864A (en) Novel compounds
AU2016380190A8 (en) Deuterated compounds for treating cancer and related diseases and conditions, and compositions and methods thereof
EA201591649A1 (ru) Составы с органическими соединениями
MX376029B (es) Compuestos de isoindol.
TR201819805T4 (tr) Flavaglin türevleri̇.
IN2013MU03862A (OSRAM)
TN2018000214A1 (en) Alkyl dihydroquinoline sulfonamide compounds